Search research articles
Contact Us
Filters
Showing results (581-590 of 598) with videos related to
Page
of 60
Sort By:
Acta Psychiatrica Scandinavica
|
June 27, 2015
Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder
S L McElroy, D E Kemp, E S Friedman, et al.
Journal of Clinical Psychopharmacology
|
December 17, 2014
Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study
William V Bobo, Noreen A Reilly-Harrington, Terence A Ketter, et al.
Journal of Affective Disorders
|
April 23, 2014
Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial
William V Bobo, Noreen A Reilly-Harrington, Terence A Ketter, et al.
The Journal of Clinical Psychiatry
|
February 5, 2016
Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder
Andrew A Nierenberg, Susan L McElroy, Edward S Friedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, et al.
ACS Medicinal Chemistry Letters
|
June 22, 2019
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer
Philip A Harris, Jill M Marinis, John D Lich, et al.
The Journal of Clinical Investigation
|
February 6, 2019
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth
Shaikamjad Umesalma, Courtney A Kaemmer, Jordan L Kohlmeyer, et al.
Journal of Burn Care & Research : Official Publication of the American Burn Association
|
January 7, 2015
A multicenter study of preventable contact burns from glass fronted gas fireplaces
Lucy Wibbenmeyer, Michael A Gittelman, Karen Kluesner, et al.
Journal of Medicinal Chemistry
|
April 26, 2016
The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase
Pamela A Haile, Bartholomew J Votta, Robert W Marquis, et al.
Journal of Medicinal Chemistry
|
July 3, 2019
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases
Pamela A Haile, Linda N Casillas, Bartholomew J Votta, et al.
Page
of 60
Search research articles
Search
Showing results (581-590 of 598) with videos related to
Sort By:
Page
of 60
Acta Psychiatrica Scandinavica
|
June 27, 2015
Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder
S L McElroy, D E Kemp, E S Friedman, et al.
Journal of Clinical Psychopharmacology
|
December 17, 2014
Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study
William V Bobo, Noreen A Reilly-Harrington, Terence A Ketter, et al.
Journal of Affective Disorders
|
April 23, 2014
Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial
William V Bobo, Noreen A Reilly-Harrington, Terence A Ketter, et al.
The Journal of Clinical Psychiatry
|
February 5, 2016
Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder
Andrew A Nierenberg, Susan L McElroy, Edward S Friedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, et al.
ACS Medicinal Chemistry Letters
|
June 22, 2019
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer
Philip A Harris, Jill M Marinis, John D Lich, et al.
The Journal of Clinical Investigation
|
February 6, 2019
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth
Shaikamjad Umesalma, Courtney A Kaemmer, Jordan L Kohlmeyer, et al.
Journal of Burn Care & Research : Official Publication of the American Burn Association
|
January 7, 2015
A multicenter study of preventable contact burns from glass fronted gas fireplaces
Lucy Wibbenmeyer, Michael A Gittelman, Karen Kluesner, et al.
Journal of Medicinal Chemistry
|
April 26, 2016
The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase
Pamela A Haile, Bartholomew J Votta, Robert W Marquis, et al.
Journal of Medicinal Chemistry
|
July 3, 2019
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases
Pamela A Haile, Linda N Casillas, Bartholomew J Votta, et al.
Page
of 60